U.S. markets open in 1 hour 5 minutes

Eloxx Pharmaceuticals, Inc. (ELOX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7700-0.1450 (-7.57%)
At close: 4:00PM EDT

1.7700 0.00 (0.00%)
Pre-Market: 8:01AM EDT

Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Currency in USD

Valuation Measures

Yahoo Finance Plus required to access annual data
Yahoo Finance Plus required to access monthly data
Subscribe to Yahoo Finance Plus Essential to download historical data
As of Date: 5/12/2021
Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 7

Trading Information

Stock Price History

Beta (5Y Monthly) 2.27
52-Week Change 3-29.20%
S&P500 52-Week Change 347.24%
52 Week High 36.7700
52 Week Low 31.7400
50-Day Moving Average 32.6240
200-Day Moving Average 33.3063

Share Statistics

Avg Vol (3 month) 3114.17k
Avg Vol (10 day) 3165.3k
Shares Outstanding 547.81M
Implied Shares Outstanding 6N/A
Float 32.14M
% Held by Insiders 11.18%
% Held by Institutions 149.30%
Shares Short (Apr 14, 2021) 41.27M
Short Ratio (Apr 14, 2021) 411.92
Short % of Float (Apr 14, 2021) 43.63%
Short % of Shares Outstanding (Apr 14, 2021) 42.66%
Shares Short (prior month Mar 14, 2021) 41.16M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Dec 19, 2017
Ex-Dividend Date 4N/A
Last Split Factor 21:20
Last Split Date 3Dec 19, 2017

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2020
Most Recent Quarter (mrq)Mar 30, 2021


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-52.07%
Return on Equity (ttm)-202.19%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -28.01M
Net Income Avi to Common (ttm)-29.32M
Diluted EPS (ttm)-0.7300
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)18.25M
Total Cash Per Share (mrq)0.38
Total Debt (mrq)14.18M
Total Debt/Equity (mrq)515.49
Current Ratio (mrq)1.57
Book Value Per Share (mrq)0.07

Cash Flow Statement

Operating Cash Flow (ttm)-23.93M
Levered Free Cash Flow (ttm)-13.34M